PLASMA EPSTEIN-BARR VIRUS (EBV) DNA AS A BIOMARKER FOR DIAGNOSIS OF SYRIAN EBV-POSITIVE BURKITT’S LYMPHOMA | ||||
| Bulletin of Pharmaceutical Sciences Assiut University | ||||
| Article 18, Volume 44, Issue 1, June 2021, Page 185-194 PDF (476.52 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bfsa.2021.174144 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Rana Habeeb1; Lina Al Hafar2; Fawza Monem 3
| ||||
| 1Department of Biochemistry and Microbiology, Faculty of Pharmacy, Damascus University, Damascus, Syria | ||||
| 2Department of Pathology, Faculty of Medicine, Damascus University, Damascus, Syria | ||||
| 3Department of Biochemistry and Microbiology, Faculty of Pharmacy, Damascus University, Damascus, Syria & Department of Clinical Laboratories, Al-Assad Hospital, Damascus University, Damascus, Syria | ||||
| Abstract | ||||
| Epstein-Barr virus - positive Burkitt’s Lymphoma is defined as the presence of Epstein-Barr virus (EBV) in tumor cells, the standard way to detect (EBV) in Burkitt’s Lymphoma is in-situ hybridization (ISH) of EBV-encoded small RNA (EBERs) in tumor cells. The present study aimed to evaluate plasma Epstein-Barr virus (EBV) DNA as a noninvasive biomarker for diagnosis and prognosis of EBV-positive Burkitt’s lymphoma. The study included 40 newly diagnosed patients with Burkitt’s lymphoma, ranging in age from 4 to 60 years, and 55 sex and age-matched controls. Forty formalin-fixed paraffin-embedded blocks of Burkitt’s lymphoma tissue samples were used to investigate the EBV by in-situ hybridization detection of the EBERs. Plasma EBV DNA was quantified by real-time quantitative polymerase chain reaction (PCR) for all Burkitt lymphoma patients prior to therapy and for control. The results showed that (22/40, 55%) of Burkitt lymphoma were positive for histological EBER, whereas plasma EBV DNA was detectable (range from 1.2×104 to 4.7×106 copies/mL) in all EBV-positive Burkitt lymphoma samples (22/22). EBV DNA was undetectable in all cases of EBV-negative Burkitt lymphomas (18/18) and all healthy control (55/55). It is worth mentioning that our results demonstrated that the EBV DNA load was significantly high in the EBV-positive BL patients suffering poor prognostic state. In conclusion: Plasma EBV-DNA can be used as a noninvasive biomarker for diagnosis and prognosis of EBV-positive Burkitt’s lymphoma. | ||||
|
Statistics Article View: 228 PDF Download: 261 |
||||
